Related Articles

• Treatment with combined dabrafenib and trametinib in BRAF^V600E-mutated metastatic malignant melanoma: a case of long-term complete response after treatment cessation
• Mycosis fungoides-type cutaneous T-cell lymphoma (MF-CTCL) epidemiology and treatment pathway in Spain: new insights for an accurate description
• Diagnosis and management of lentigo maligna: a review

Article Page

Atopic dermatitis is a highly prevalent chronic, immune-mediated inflammatory skin disease with a significant burden on patients, families and healthcare systems. This article presents recommendations developed by the Atopic Dermatitis Group of the Portuguese Society of Dermatology and Venereology addressing several clinical questions that arise in the management and care of moderate-to-severe atopic dermatitis with biologic agents and Janus kinase (JAK) inhibitors based on the available evidence. The recommendations were generated after a thorough evaluation of existing guidelines on the treatment of atopic dermatitis, publications concerning new biologics and JAK inhibitors not yet incorporated into existing guidelines, and expert-based recommendations. It also includes considerations on atopic dermatitis severity, indications for initiating biologic agents and JAK inhibitors, parameters to be considered in the treatment choice, in particular treatment goals, and recommendations for the use, screening and monitoring of these therapies.

Keywords: atopic dermatitis, biologic therapy, guidelines, JAK inhibitors, recommendations, treatment goals.

Citation: Torres T, Gonçalo M, Paiva Lopes MJ, Claro C, Ramos L, Selores M, Mendes Bastos P, Rocha J, Carvalho R, Mota A, Filipe P on Behalf of the Atopic Dermatitis Group of the Portuguese Society of Dermatology and Venereology. Portuguese recommendations for the treatment of atopic dermatitis with biologic therapy and JAK inhibitors in adult patients. Drugs Context. 2021;10:2021-9-5. https://doi.org/10.7573/dic.2021-9-5

Contributions: All authors contributed equally to the preparation of this review. All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.

Disclosure and potential conflicts of interest: TT has received research grants and/or consulting fees from AbbVie, Almirall, Amgen, Arena Pharmaceuticals, Biocad, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Eli Lilly, Janssen, LEO Pharma, MSD, Novartis, Pfizer, Samsung-Bioepis, Sandoz and Sanofi. MG has received research grants and/or consulting fees from Abbvie, Leo, Lilly, Novartis, Pfizer, Sanofi and Takeda. MJPL has received research grants and/or consulting fees from AbbVie, Almirall, Janssen, Leo-Pharma, Lilly, Novartis, Pfizer, Sanofi and Viatris. CC has received research grants and/or consulting fees from Janssen, Sanofi-Genzyme, Procter&Gamble, Astellas, Galderma, Leo-Pharma and Mylan. MS has received research grants and/or consulting fees from Janssen, Novartis and Pfizer. PMB has received research grants and/ or consulting fees from AbbVie, Pfizer, Janssen, LEO Pharma, Novartis, Sanofi, Teva, Bayer and L’Oreal. LR, JR, RC, AM and PF have no conflicts of interest to declare. The International Committee of Medical Journal Editors (ICMJE) Potential Conflicts of Interests form for the authors is available for download at: https://www.drugsincontext.com/wp-content/uploads/2021/11/dic.2021-9-5-COI.pdf

Acknowledgements: None.

Funding declaration: There was no funding associated with the preparation of this article.

Copyright: Copyright © 2021 Torres T, Gonçalo M, Paiva Lopes MJ, Claro C, Ramos L, Selores M, Mendes Bastos P, Rocha J, Carvalho R, Mota A, Filipe P on Behalf of the Atopic Dermatitis Group of the Portuguese Society of Dermatology and Venereology. Published by Drugs in Context under Creative Commons License Deed CC BY NC ND 4.0 which allows anyone to copy, distribute and transmit the article provided it is properly attributed in the manner specified below. No commercial use without permission.

Correct attribution: Copyright © 2021 Torres T, Gonçalo M, Paiva Lopes MJ, Claro C, Ramos L, Selores M, Mendes Bastos P, Rocha J, Carvalho R, Mota A, Filipe P on Behalf of the Atopic Dermatitis Group of the Portuguese Society of Dermatology and Venereology. https://doi.org/10.7573/dic.2021-9-5. Published by Drugs in Context under Creative Commons License Deed CC BY NC ND 4.0.

Article URL: https://www.drugsincontext.com/portuguese-recommendations-for-the-treatment-of-atopic-dermatitis-with-biologic-therapy-and-jak-inhibitors-in-adult-patients

Correspondence: Tiago Torres, Serviço de Dermatologia, Centro Hospitalar do Porto, Edifício das Consultas Externas, Ex. CICAP, Rua D. Manuel II, s/n, 4100 Porto, Portugal. Email: torres.tiago@outlook.com

Provenance: Invited; externally peer reviewed.

Submitted: 23 September 2021; Accepted: 23 November 2021; Publication date: 30 December 2021.

Drugs in Context is published by BioExcel Publishing Ltd. Registered office: Plaza Building, Lee High Road, London, England, SE13 5PT.

BioExcel Publishing Limited is registered in England Number 10038393. VAT GB 252 7720 07.

For all manuscript and submissions enquiries, contact the Editorial office editorial@drugsincontext.com

For all permissions, rights and reprints, contact David Hughes david.hughes@bioexcelpublishing.com